90-Second Read: Dyadic (NASDAQ: DYAI) and Scripps launch Hantavirus antibody collaboration

Dyadic International and Scripps Research team up to evaluate Hantavirus antibody and vaccine candidates using Dyadic's C1 platform for rapid, scalable biologic manufacturing. Dyadic International announced a collaboration between Dyadic Applied BioSolutions and researchers at Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting Hantaviruses, including the Andes virus strain associated with Hantavirus Pulmonary Syndrome. Forward-looking statements involve many risks, uncertainties, or other factors beyond Dyadic's control. The work will assess Dyadic's microbial fungal-based C1 platform for rapid development, high-productivity fermentation, and large-scale biologic manufacturing aimed at future infectious disease preparedness.

Dyadic recently highlighted growing commercial activity with recombinant proteins and enzymes in non-pharmaceutical applications, including animal-free proteins for life sciences, cell culture media, nutrition, wellness, and industrial markets. Forward-looking statements generally can be identified by use of the words "expect," "should," "intend," "anticipate," "will," "project," "may," "might," "potential," or "continue" and other similar terms or variations of them or similar terminology. Dyadic International, Inc., and its subsidiaries caution readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Together, these programs continue to generate data that support the potential advantages of the C1 platform, including compressed development timelines, scalable microbial fermentation, and streamlined manufacturing processes.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Such information shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.